Real-World Evaluation of Efficacy and Tolerability of Immune Globulin Subcutaneous 16.5% in the Treatment of Patients with Primary Immunodeficiency

Immune Globulin Subcutaneous (Human), 16.5% solution (IGSC 16.5%) is a new subcutaneous immunoglobulin for the treatment of primary immunodeficiencies (PID). Available from Octapharma as Cutaquig ® since May 2019, we report the first real-world data regarding use of IGSC 16.5%.

Source: Journal of Allergy and Clinical Immunology - January 31, 2020 Category: Allergy & Immunology Authors: Richard Herrscher, Jeffrey Langford, Samantha Kuten, Lucinda Van Anglen Source Type: research